Mauro Cozzolino

Dr. Mauro Cozzolino

Institute of Translational Pharmacology, National Research Council, Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Progress in Neurobiology
Verified
Journal Article
Closed access
Mauro CozzolinoMauro Cozzolino
Mauro Cozzolino
MCMaria Teresa Carrì
Maria Teresa Carrì

12 September 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AFAlberto Ferri
Alberto Ferri
Mauro CozzolinoMauro Cozzolino
Mauro Cozzolino
CCClaudia Crosio
Claudia Crosio
MNMonica Nencini
Monica Nencini
ACArianna Casciati
Arianna Casciati
MCMaria Teresa Carrì
Maria Teresa Carrì
Recent studies suggest that the toxicity of familial amyotrophic lateral sclerosis mutant Cu, Zn superoxide dismutase (SOD1) arises from its selective recruitment to mitochondria. Here we demonstrate that each of 12 different familial ALS-mutant SOD1s with widely differing biophysical properties are associated with mitochondria of motoneuronal cells to a much greater extent than wild-type SOD1, and that this effect may depend on the oxidation of Cys residues. We demonstrate further that mutant SOD1 proteins associated with the mitochondria tend to form cross-linked oligomers and that their presence causes a shift in the redox state of these organelles and results in impairment of respiratory complexes. The observation that such a diverse set of mutant SOD1 proteins behave so similarly in mitochondria of motoneuronal cells and so differently from wild-type SOD1 suggests that this behavior may explain the toxicity of ALS-mutant SOD1 proteins, which causes motor neurons to die.

1 August 2003 in Brain Research Bulletin
Verified
Journal Article
Closed access
MCMaria Teresa Carrı̀
Maria Teresa Carrı̀
AFAlberto Ferri
Alberto Ferri
Mauro CozzolinoMauro Cozzolino
Mauro Cozzolino
LCLilia Calabrese
Lilia Calabrese
GRGiuseppe Rotilio
Giuseppe Rotilio

1 March 2008 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
Mauro CozzolinoMauro Cozzolino
Mauro Cozzolino
AFAlberto Ferri
Alberto Ferri
MCMaria Teresa Carrì
Maria Teresa Carrì
Amyotrophic lateral sclerosis (ALS) is a late-onset progressive degeneration of motor neurons occurring both as a sporadic and a familial disease. The etiology of ALS remains unknown, but one fifth of instances are due to specific gene defects, the best characterized of which is point mutations in the gene coding for Cu/Zn superoxide dismutase (SOD1). Because sporadic and familial ALS affect the same neurons with similar pathology, it is hoped that understanding these gene defects will help in devising therapies effective in both forms. A wealth of evidence has been collected in rodents made transgenic for mutant SOD1, which represent the best available models for familial ALS. Mutant SOD1 likely induces selective vulnerability of motor neurons through a combination of several mechanisms, including protein misfolding, mitochondrial dysfunction, oxidative damage, cytoskeletal abnormalities and defective axonal transport, excitotoxicity, inadequate growth factor signaling, and inflammation. Damage within motor neurons is enhanced by noxious signals originating from nonneuronal neighboring cells, where mutant SOD1 induces an inflammatory response that accelerates disease progression. The clinical implication of these findings is that promising therapeutic approaches can be derived from multidrug treatments aimed at the simultaneous interception of damage in both motor neurons and nonmotor neuronal cells.

15 May 2013 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Savina ApolloniSavina Apolloni
Savina Apolloni
CPChiara Parisi
Chiara Parisi
MPMaria Grazia Pesaresi
Maria Grazia Pesaresi
SRSimona Rossi
Simona Rossi
MCMaria Teresa Carrì
Maria Teresa Carrì
Nadia D'AmbrosiNadia D'Ambrosi
Nadia D'Ambrosi
Inflammation and oxidative stress are thought to play determinant roles in the pathogenesis of amyotrophic lateral sclerosis (ALS). Degenerating motor neurons produce signals that activate microglia to release reactive oxygen species (ROS) and proinflammatory cytokines, resulting in a vicious cycle of neurodegeneration. The ALS-causing mutant protein Cu+/Zn+ superoxide dismutase SOD1-G93A directly enhances the activity of the main ROS-producing enzyme in microglia, NADPH oxidase 2 (NOX2), a well-known player in the pathogenesis of ALS. Considering that extracellular ATP through P2X7 receptor constitutes a neuron-to-microglia alarm signal implicated in ALS pathology, we used primary microglial cells derived from transgenic SOD1-G93A mice and SOD1-G93A mice lacking the P2X7 receptor to investigate the effects of both pharmacological induction and genetic ablation of receptor activity on the NOX2 pathway. We observed that, in SOD1-G93A microglia, the stimulation of P2X7 receptor by 2′-3′-O-(benzoyl-benzoyl) ATP enhanced NOX2 activity in terms of translocation of p67phox to the membrane and ROS production; this effect was totally dependent on Rac1. We also found that, following P2X7 receptor stimulation, the phosphorylation of ERK1/2 was augmented in ALS microglia, and there was a mutual dependency between the NOX2 and ERK1/2 pathways. All of these microglia-mediated damaging mechanisms were prevented by knocking out P2X7 receptor and by the use of specific antagonists. These findings suggest a noxious mechanism by which P2X7 receptor leads to enhanced oxidative stress in ALS microglia and identify the P2X7 receptor as a promising target for the development of therapeutic strategies to slow down the progression of ALS.

1 January 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Mauro CozzolinoMauro Cozzolino
Mauro Cozzolino
IAIlaria Amori
Ilaria Amori
MPMaria Grazia Pesaresi
Maria Grazia Pesaresi
AFAlberto Ferri
Alberto Ferri
MNMonica Nencini
Monica Nencini
MCMaria Teresa Carrì
Maria Teresa Carrì
Converging evidence indicates that aberrant aggregation of mutant Cu,Zn-superoxide dismutase (mutSOD1) is strongly implicated in familial amyotrophic lateral sclerosis (FALS). MutSOD1 forms high molecular weight oligomers, which disappear under reducing conditions, both in neural tissues of FALS transgenic mice and in transfected cultured cells, indicating a role for aberrant intermolecular disulfide cross-linking in the oligomerization and aggregation process. To study the contribution of specific cysteines in the mechanism of aggregation, we mutated human SOD1 in each of its four cysteine residues and, using a cell transfection assay, analyzed the solubility and aggregation of those SOD1s. Our results suggest that the formation of mutSOD1 aggregates are the consequence of covalent disulfide cross-linking and non-covalent interactions. In particular, we found that the removal of Cys-111 strongly reduces the ability of a range of different FALS-associated mutSOD1s to form aggregates and impair cell viability in cultured NSC-34 cells. Moreover, the removal of Cys-111 impairs the ability of mutSOD1s to form disulfide cross-linking. Treatments that deplete the cellular pool of GSH exacerbate mutSOD1s insolubility, whereas an overload of intracellular GSH or overexpression of glutaredoxin-1, which specifically catalyzes the reduction of protein-SSG-mixed disulfides, significantly rescues mutSOD1s solubility. These data are consistent with the view that the redox environment influences the oligomerization/aggregation pathway of mutSOD1 and point to Cys-111 as a key mediator of this process.